99 related articles for article (PubMed ID: 26433907)
1. Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities.
Goldberg SL
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):711-4. PubMed ID: 26433907
[TBL] [Abstract][Full Text] [Related]
2. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
Goldberg SL; Akard LP; Dugan MJ; Faderl S; Pecora AL
J Oncol Pract; 2015 May; 11(3):e398-404. PubMed ID: 25758446
[TBL] [Abstract][Full Text] [Related]
3. Milestones and monitoring.
Morotti A; Fava C; Saglio G
Curr Hematol Malig Rep; 2015 Jun; 10(2):167-72. PubMed ID: 25921389
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Luu MH; Press RD
Expert Rev Mol Diagn; 2013 Sep; 13(7):749-62. PubMed ID: 24063401
[TBL] [Abstract][Full Text] [Related]
5. Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners.
Akard LP; Wang YL
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):385-95. PubMed ID: 21723805
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
7. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
J Med Econ; 2014 Feb; 17(2):89-98. PubMed ID: 24188054
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Ou J; Vergilio JA; Bagg A
Am J Hematol; 2008 Apr; 83(4):296-302. PubMed ID: 17957805
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
[TBL] [Abstract][Full Text] [Related]
11. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
12. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Goldberg SL; Chen L; Guerin A; Macalalad AR; Liu N; Kaminsky M; Ericson SG; Wu EQ
Curr Med Res Opin; 2013 Sep; 29(9):1075-82. PubMed ID: 23738923
[TBL] [Abstract][Full Text] [Related]
13. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
14. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
16. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
17. Molecular monitoring of response in patients with chronic myeloid leukemia.
Kolibaba KS
Manag Care; 2013 Jul; 22(7):40, 50-61. PubMed ID: 23936973
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa.
Sissolak G; Badenhorst J; Steenkamp J; Heaney M; Louw V; Schnugh D; Willem P
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):803-10. PubMed ID: 26481837
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
20. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]